Avrobio has shared data on the first Gaucher disease patient to receive its gene therapy AVR-RD-02. The patient, who was stable on enzyme replacement therapy at baseline, experienced a 22% drop in a toxic metabolite after receiving AVR-RD-02 and stopping taking the standard of care.

Gaucher, like the Fabry disease targeted by Avrobios lead prospect, is currently treated using enzyme replacement therapies sold by Sanofi and Takeda, which entered the market through its takeover of Shire. However, a significant minority of patients experience physical limitations despite treatment. Negative outcomes include bone pain and spleen enlargement. Johnson & Johnsons Zavesca offers an oral alternative, but there remain unmet medical needs.

Avrobio is developing AVR-RD-02 to address those needs. The data shared as part of Avrobios R&D day mark the start of the effort to show AVR-RD-02 performs as hoped in the clinic.

Start using real-world data to advance your clinical research

Much has been written about the promise of real-world data (RWD) in life sciences, but how does it work in practice? We address this question in a new whitepaper that demonstrates the potential benefits of new RWD technologies with a proof of concept study to show how RWD can be incorporated into clinical research.

The first patient to receive AVR-RD-02 discontinued enzyme replacement therapy one month before taking the gene therapy. Three months after receiving the gene therapy, levels of Gaucher biomarker lyso-Gb1 had fallen 22%. The patients level of plasma chitotriosidase, a biomarker of cells associated with severe organ damage, was down 17%. Hemoglobin and platelets were in the normal range.

AVR-RD-02 triggered those changes without causing serious adverse events. The data drop offers an early indication that Avrobio may be able to improve outcomes by harvesting hematopoietic stem cells, adding a gene that encodes for glucocerebrosidase and reinfusing the cells back into the same patient. With enzyme replacement therapies costing healthcare systems up to $400,000 a year per patient, there is scope for AVR-RD-02 to cut the cost of treating Gaucher disease.

Avrobio shared the early look at clinical data on AVR-RD-02 alongside updates about other assets. There is now more than three years of data on some Fabry patients treated with Avrobios lead asset, putting the company in a position to plot a path to accelerated approval. Avrobio plans to submit its briefing book to the FDA by the end of the year to align on an accelerated approval strategy.

The update also covered cystinosis candidate AVR-RD-04. The first patient to receive the candidate is off oral and eye drop cysteamine 12 months after receiving the gene therapy. The number of crystals in the patients skin are down 56%, leading Avrobio to posit they may have gained the ability to make their own functional cystinosin protein.

Follow this link:
Avrobio tracks improvements in first patient treated with Gaucher gene therapy - FierceBiotech

Skin Stem Cells Comments Off on Avrobio tracks improvements in first patient treated with Gaucher gene therapy – FierceBiotech | November 20th, 2020

Voters in California have approved Proposition 14, which will pump billions of dollars into the state's stem cell research program. The Associated Press called the vote on Thursday, with 51 percent of ballots for and 49 percent against.

The result will allow the state to borrow $5.5 billion from investors for its stem cell agency, the California Institute for Regenerative Medicine (CIRM). The moneywhich taxpayers will repay with interest over the next 30 yearswill enable the institute to stay open, expand its research programs, and build new facilities.

Some $1.5 billion of the money will be spent researching conditions affecting the brain and central nervous system, such as Alzheimer's, Parkinson's, epilepsy, and stroke.

Unlike specialized cellssuch as blood cells or bone cellsstem cells do not have a specific job. Think of them as the raw materials of our bodies. When they divide, they can either renew and make new stem cells, or turn into specialized cells.

Despite making headlines for years, stem cell research is still in its early stages, with some treatments that have appeared to have worked in animals now going into clinical trials. These include treatments for macular degeneration, a common cause of blindness, as well as stroke, Lou Gehrig's disease, and spinal cord injuries.

It is hoped growing stem cells into specialized cells could also one day be used to replace damaged tissue and organs, for instance by helping the pancreas produce insulin in people with diabetes.

Currently, stem bone marrow transplantation is the most common form of stem cell therapy, used to treat blood cancer patients. Stem cell therapy has also been used for grafts of corneal stem cells, as well as skin grafts for burns victims.

As well as creating treatments, stem cell research can also help scientists understand diseases. Observing the cells in a lab as they turn into specialized cells, for instance, can provide clues on how we develop certain conditions.

There are a number of stem cells: embryonic stem cells, adult stem cells, adult stem cells tweaked to behave like embryonic stem cells, and stem cells found in the amniotic fluid and the umbilical cord of babies.

The controversy around stem cell research largely lies in the use of embryonic stem cells. These are taken from human embryos in their early stages of development. Opponents have likened this to abortion, although others disagree with this stance.

Embryonic stem cells used in research come from donations from IVF clinics, where an egg is fertilized with a sperm but not implanted into a patient because it is not needed. Embryonic stem cells are preferred over adult stem cells, as it may not be possible to specialize the latter and they are more likely to have abnormalities. But research suggests that it may be possible to turn adult stem cells into a wider range of specialized cells than previously thought, which may make them more useful.

In 2001, the Bush administration banned federal funding for stem cell research. This lead real estate developer Robert N. Klein II to initiate and help fund Proposition 71 in California. The aim was to enshrine the right to carry out stem cell research in the state's constitution, and establish CIRM. Klein was motivated by his son's experience with Type 1 diabetes, and his mother's Alzheimer's diagnosis. In 2004, Californians voted in favor of the proposition.

The institute has performed 64 clinical trials, and published over 3,000 scientific articles on the subject. But 16 years after Proposition 71 passed, CIRM started to run out of funds, and stopped accepting applications for new projects last year. This prompted the Californians for Stem Cell Research, Treatments and Cures political action committee (PAC) to lead the campaign for Proposition 14. Klein was among its supporters, as well as California governor Gavin Newsom, LA mayor Eric Garcetti, and the Michael J. Fox Foundation established by the Back to the Future actor and Parkison's disease patient who is its namesake.

On November 1, the foundation urged people via Twitter to vote in favor of Prop 14 to fund research on neurological disease. "Without this proposition vital research may come to a halt, delaying new treatments for people with," it said.

Read the rest here:
As California Passes Prop 14, What Is Stem Cell Research and Why Is It Controversial? - Newsweek

Skin Stem Cells Comments Off on As California Passes Prop 14, What Is Stem Cell Research and Why Is It Controversial? – Newsweek | November 18th, 2020

The company's active ingredient product lines meet consumer expectations of quality, performance, and sustainability

LONDON, Nov. 18, 2020 /PRNewswire/ --Based on its recent analysis of the global personal care active ingredientsmarket, Frost & Sullivan recognizes Mibelle AG Biochemistry with the 2020 Global Company of the Year Award. It has successfully introduced several breakthrough sustainable active ingredients, whose efficacy is shttps://mma.prnewswire.com/media/1337466/Mibelle_Award.jpg upported by in-vivo and in-vitro study results. Mibelle is a pioneer with regards to using senolytics to delay skin aging in cosmetic applications, which has helped the company achieve a leading positioning in the market.

Photo - https://mma.prnewswire.com/media/1337466/Mibelle_Award.jpg

Click here to view the full multimedia release: https://best-practices.frost.com/mibelle-biochemistry/

"Demonstrating its expertise in recognizing the dynamic needs of the cosmetics industry, Mibelle launched the Alpine Rose Active line of products to fight skin aging,"said Prateeksha Kaul Research Analyst. "This line of products uses a natural senolytic agent extracted from the Alpine rose leaves in the Swiss Alps to eliminate senescent cells, which are the cells responsible for aging, without affecting the neighboring cells. This halts the skin's aging process while rejuvenating it and increasing its elasticity. This product also meets the rising demand for natural and sustainable products over harsh chemicals that are harmful to both the environment and the skin."

Similarly, in response to the growing interest in phytocannabinods, Mibelle introduced an encapsulated cannabidiol (CBD) product, the Lipobelle Pino C. Other players in the market have had limited success with CBD in spite of its potential benefits for the skin because it is not soluble in water. Mibelle addressed this limitation with the Lipobelle Pino C. By encapsulating the CBD into a nanoemulsion using hemp oil, Mibelle made it water-soluble and stable in cosmetic formulations. Its combination with an extract from Swiss stone pines also helps the product fight inflammation. Lipobelle Pino C exploits the anti-inflammatory and regenerating effects of CBD for cosmetic benefits such as easing facial tension, reducing inflammation, and regenerating tissue.

Mibelle has been a pioneer in utilizing interesting biochemical concepts for its active ingredients. In 2008, it gained a first-mover advantage with the launch of its active ingredient PhytoCellTec Malus Domestica, which involved the application of stem cells in cosmetics for the very first time. In 2019, Mibelle utilized its PhytoCellTec technology to launch the PhytoCellTec Goji, which stimulates the mesenchymal stem cell (MSC) culture with goji stem cells for enhancing face shape by preventing the skin from sagging. The success of this technology and other recent innovations has allowed the company to achieve a 15 percent growth rate annually.

"Mibelle works closely with certification bodies to analyze the ingredients, raw materials, and processes to obtain the required certifications for its products. It also collaborates with personal care product manufacturers to offer premium high-quality products that benefit the end user," noted Kaul. "With its ability to introduce breakthrough active ingredients, Mibelle AG Biochemistry has carved a niche for itself in the personal care industry. It has consistently adopted a holistic innovation approach that has enabled it to consistently develop novel concepts and ingredients."

Each year, Frost & Sullivan presents a Company of the Year award to the organization that demonstrates excellence in terms of growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:

Harley GadomskiP: 12104778469E: [emailprotected]

About Mibelle AG Biochemistry

Mibelle Biochemistry designs and develops innovative, high-quality actives based on naturally derived compounds and profound scientific know-how. Inspired by nature - Realized by Science.

For more information on Mibelle Biochemistry, please visit http://www.mibellebiochemistry.com

Contact:

Esther Belser Mibelle Biochemistry, SwitzerlandHead of MarketingPhone: +41 62 836 13 47Email: [emailprotected]

http://www.frost.com

SOURCE Frost & Sullivan

Continue reading here:
Mibelle Biochemistry's Ability to Introduce Breakthrough Active Ingredients for the Personal Care Market Lauded by Frost & Sullivan - PR Newswire...

Skin Stem Cells Comments Off on Mibelle Biochemistry’s Ability to Introduce Breakthrough Active Ingredients for the Personal Care Market Lauded by Frost & Sullivan – PR Newswire… | November 18th, 2020

18-Nov-2020

Ingredients | Marketing

The company's active ingredient product lines meet consumer expectations of quality, performance andsustainability

Based on its recent analysis of the global personal care active ingredients market, Frost & Sullivan recognises Mibelle AG Biochemistry with the 2020 Global Company of the Year Award.

It has successfully introduced several breakthrough sustainable active ingredients, whose efficacy is supported by in-vivo and in-vitro study results. Mibelle Biochemistry is a pioneer with regards to using senolytics to delay skin aging in cosmetic applications, which has helped the company achieve a leading positioning in the market.

"Demonstrating its expertise in recognising the dynamic needs of the cosmetics industry, Mibelle Biochemistry launched the Alpine Rose Active ingredient to fight skin aging," said Prateeksha Kaul Research Analyst.

"This ingredient contains a natural senolytic agent extracted from the Alpine rose leaves in the Swiss Alps to eliminate senescent cells, which are the cells responsible for ageing, without affecting the neighboring cells.

"This halts the skins aging process while rejuvenating it and increasing its elasticity. This active also meets the rising demand fornatural and sustainable products over harsh chemicals that are harmful to both the environment and the skin."

Similarly, in response to the growing interest in phytocannabinods, Mibelle Biochemistry introduced an encapsulated cannabidiol (CBD) ingredient, the Lipobelle Pino C. Other players in the market have had limited success with CBD in spite of its potential benefits for the skin because it is not soluble in water.

Mibelle addressed this limitation with the Lipobelle Pino C. By encapsulating the CBD into a nanoemulsion using hemp oil, Mibelle made it water-soluble and stable in cosmetic formulations.

Its combination with an extract from Swiss stone pines also helps the product fight inflammation. Lipobelle Pino C exploits the anti-inflammatory and regenerating effects of CBD for cosmetic benefits such as easing facial tension, reducing inflammation, and regenerating tissue.

Mibelle Biochemistry has been a pioneer in utilising interesting biochemical concepts for its active ingredients. In 2008, it gained a first-mover advantage with the launch of its active ingredient PhytoCellTec Malus Domestica, which involved the application of stem cells in cosmetics for the very first time.

In 2019, Mibelle utilised its PhytoCellTec technology to launch the PhytoCellTec Goji, which stimulates the mesenchymal stem cell (MSC) culture with goji stem cells for enhancing face shape by preventing the skin from sagging. The success of this technology and other recent innovations has allowed the company to achieve a 15 percent growth rate annually.

Each year, Frost & Sullivan presents a Company of the Year award to the organisation that demonstrates excellence in terms of growth strategy and implementation in its field.

The award recognises a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and marketpenetration.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development.

Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

Visit link:
Mibelle Biochemistry announces: Mibelle Biochemistrys Ability to Introduce Breakthrough Active Ingredients for the Personal Care Market by Frost and...

Skin Stem Cells Comments Off on Mibelle Biochemistry announces: Mibelle Biochemistrys Ability to Introduce Breakthrough Active Ingredients for the Personal Care Market by Frost and… | November 18th, 2020

A doll-obsessed couple describe themselves as human Barbie and Ken.

The Los Angeles-based pair have had futuristic stem-cell injections to achieve their looks.

Marcela Iglesias and her husband Steven Berman get the treatment in the hope of rejuvenating their bodies, skin and hair.

The former said: "Weve both had stem cell therapy through IV.

Thirty million mysenthanial cells each a total of 60 million stem cells through the drip.

The 43-year-old has also turned back the clock by getting 60,000 worth of cosmetic procedures.

As well as this, Marcela hones her sculpted figure by following a gruelling fitness regime.

She said: "I never had plastic surgery but I am not against it just a couple of cosmetic procedures like Botox and a little filler to maintain face volume, but have never completely changed or modified my appearance.

"The Barbie doll is an inspiration for becoming whoever you want to be and achieving all your life goals.

Obviously, the aesthetic of the doll is impeccable but at the same time, my approach is a more natural look and I achieve it by working out all the time on my Edgecross-X training system.

"Surgery-wise, I have been contemplating a mini facelift but with the new Morpheus 8, a non-surgical advanced needling treatment that uses radio frequency to tighten and smooth wrinkles on the face and body.

Marcela added: I am also considering a boob and booty boost, basically to make them perky and firm again.

"I admire what the doll represents more than how she looks; I am very respectful of the image of the Barbie doll as I want to encourage all men and women around the world to pursue their dreams and to achieve the look they want.

While the Barbie fan hasnt had any invasive plastic ops done, her Ken doll-loving husband has.

Steven 53, has had a chin implant, two hair transplantations and neck surgery.

The couples extreme appearance helps them to stand out on the street.

Marcela said: "When we go out together, people tell us that we look like Barbie and Ken because we are both blonde and have the doll-like aesthetic.

"I always wear vibrant colours. We break the mould I guess.

The couple, who have been together since meeting on Myspace in 2009, seem to enjoy the attention their looks bring.

Their fame has allowed them to buy McLaren 570s sports cars that cost 200,000.

The motor features an oil-slick rainbow paint job, courtesy of hit TV show Pimp My Ride's West Coast Customs in Los Angeles.

Marcela, who sometimes goes by the nickname 'Queen of Hollywood' and shares glossy lifestyle shots with 310,000 followers on Instagram page @marcelaiglesiashollywood, added: "This type of car is more like a fulfilling a fantasy and achieving one of my dreams.

"I always wanted a car where the doors open like angel wings, so this year with everything that's been going on, I decided to treat myself and my husband.

"I must admit that I had to compromise on the colour because I originally wanted something more pinky toned, but my husband has to drive the car as well and I didn't want him to feel embarrassed!

I believe this car is an extension of my personality - a reflection of myself... I dress the car like I would like to dress!

Here is the original post:
Real life 'Barbie and Ken' achieve doll-like looks with futuristic stem-cell injections - Daily Star

Skin Stem Cells Comments Off on Real life ‘Barbie and Ken’ achieve doll-like looks with futuristic stem-cell injections – Daily Star | November 18th, 2020

Market Report Summary

For Full Information -> Click Here

Read Full Press Release Below

The healthcare industry has been focusing on excessive research and development in the last couple of decades to ensure that the need to address issues related to the availability of drugs and treatments for certain chronic diseases is effectively met. Healthcare researchers and scientists at the Li Ka Shing Faculty of Medicine of the Hong Kong University have successfully demonstrated the utilization of human induced pluripotent stem cells or hiPSCs from the skin cells of the patient for testing therapeutic drugs.

The success of this research suggests that scientists have crossed one more hurdle towards using stem cells in precision medicine for the treatment of patients suffering from sporadic hereditary diseases. iPSCs are the new generation approach towards the prevention and treatment of diseases that takes into account patients on an individual basis considering their genetic makeup, lifestyle, and environment. Along with the capacity to transform into different body cell types and same genetic composition of the donors, hiPSCs have surfaced as a promising cell source to screen and test drugs.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/17968

Company Profile

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/17968

In the present research, hiPSC was synthesized from patients suffering from a rare form of hereditary cardiomyopathy owing to the mutations in Lamin A/C related cardiomyopathy in their distinct families. The affected individuals suffer from sudden death, stroke, and heart failure at a very young age. As on date, there is no exact treatment available for this condition.

This team in Hong Kong tested a drug named PTC124 to suppress specific genetic mutations in other genetic diseases into the iPSC transformed heart muscle cells. While this technology is being considered as a breakthrough in clinical stem cell research, the team at Hong Kong University is collaborating with drug companies regarding its clinical application.

The unique properties of iPS cells provides extensive potential to several biopharmaceutical applications. iPSCs are also used in toxicology testing, high throughput, disease modeling, and target identification. This type of stem cell has the potential to transform drug discovery by offering physiologically relevant cells for tool discovery, compound identification, and target validation.

A new report by Persistence Market Research (PMR) states that the globalinduced pluripotent stem or iPS cell marketis expected to witness a strong CAGR of 7.0% from 2018 to 2026. In 2017, the market was worth US$ 1,254.0 Mn and is expected to reach US$ 2,299.5 Mn by the end of the forecast period in 2026.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/17968

Customization to be the Key Focus of Market Players

Due to the evolving needs of the research community, the demand for specialized cell lines have increased to a certain point where most vendors offering these products cannot depend solely on sales from catalog products. The quality of the products and lead time can determine the choices while requesting custom solutions at the same time. Companies usually focus on establishing a strong distribution network for enabling products to reach customers from the manufacturing units in a short time period.

Entry of Multiple Small Players to be Witnessed in the Coming Years

Several leading players have their presence in the global market; however, many specialized products and services are provided by small and regional vendors. By targeting their marketing strategies towards research institutes and small biotechnology companies, these new players have swiftly established their presence in the market.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Website https://www.persistencemarketresearch.com

More here:
The Induced Pluripotent Stem Cells Market To Witness Fierce Competition Amongst The Key Players - KYT24

Skin Stem Cells Comments Off on The Induced Pluripotent Stem Cells Market To Witness Fierce Competition Amongst The Key Players – KYT24 | November 18th, 2020

What is the value of time? La Prairie has been pondering that question for nearly a century, since founder Dr. Paul Niehans, who earned the sobriquet father of cellular therapy, began experimenting with remedies for longevity in 1931 at the Clinique La Prairie in Montreux, Switzerland.

Over the years, the heritage Swiss luxury house has lived at the forefront of beauty innovation, producing indulgent face creams and serums that introduce science into skincare and incorporate rarefied ingredients such as caviar, gold, and now platinum. The precious metal is the anchor of new the Platinum Rare Haute-Rejuvenation collection, the brands latest fountain-of-youth formula offered in a seven product range.

Housed in an assortment of sculptural, amethyst-shaded vessels with enhanced platinum accents, the velvety creams and elixirsperfumed with La Prairies signature scentshowcase a new science dubbed Haute-Rejuvenation. At the core of it is a cellular renewal process that smooths wrinkles, improves skin moisture, restores volume, and induces a vibrant glow. By invigorating epidermal stem cells, it in effectturns back time to more youthful skin.

La Prairies Exclusive Cellular Complex is a life force for the skin. It uses biotechnological research to give new life and energy back to the very cells where beauty is born. It invigorates and nourishes epidermal stem cells to enable them to resume cellular renewal and functionality similar to that of young skin.

When we age, the skins natural rejuvenating capacity decreases, leading to the appearance of signs of aging, says Dr. Jacqueline Hill, the brands global director of strategic innovation. La Prairies Science of Haute-Rejuvenation seeks to specifically modulate and stimulate the skins natural network of interconnected rejuvenating processes to compensate for the age-related decrease of its performance.

Another pillar of the brands history is art. To celebrate the launch of Platinum RareHaute Rejuvenation, La Prairie commissioned the acclaimed British composer Max Richter and Japanese artist Nobuhiro Nakanishi to collaborate on an immersive installation set to debut at this years West Bund Art & Design in Shanghai (Nov. 12-15). Richter masterminded a score for Nakanishis layer drawing Echo of Time, a sculptural work with a sequential photography series of the Swiss Alps at twilight.

The duo was tasked to consider the essence of time and space, particularly a billion -year-long meteor shower responsible for bringing platinum to earth. For his contribution, Nakanishi traveled to Niederhorn peak in the Swiss Alps where he photographed a vibrant sunrise of blue, red, and purplethe colors that imbue Platinum Rares bottle design. The colors dyed the mountains and at the same time, the sky awakened and became amethyst, Nakanishi says of the scene. The mountainous scenery in Switzerland is the perfect place to illustrate the notion of timeless nature through the clearness of the water, the air, and the reflection of light created by nature itself.

Richters melodic composition begins with pulsating choral strings that give way to an individual acoustic figure meant to stimulate the feeling of entering a new landscape. It provokes a dynamic encounter with a new world and makes you feel alive, he says. To Richter, time is mysterious and doesnt always move at the same speed. This is the kind of thing a piece of music can trigger: it can stop time or speed it up, it can make time feel more intense.

Its a synergetic notion: Manipulating the effects of time is something La Prairie does best.

Read the original post:
La Prairies New Collection Is Inspired by a Platinum Meteor Shower that Lasted 200 Million Years - Surface Magazine

Skin Stem Cells Comments Off on La Prairies New Collection Is Inspired by a Platinum Meteor Shower that Lasted 200 Million Years – Surface Magazine | November 18th, 2020

PARIS, FRANCE - OCTOBER 06: A model walks the runway during the Chanel Womenswear Spring/Summer 2021 ... [+] show as part of Paris Fashion Week on October 06, 2020 in Paris, France. (Photo by Stephane Cardinale - Corbis/Corbis via Getty Images)

In 2020, a symbol of confidence is the perfect companion as the year (thankfully) comes to a close. Americans are turning over a new leaf after being quarantined and pushed forward growing accustomed to a home-hibernated lifestyle. Nowadays, breaking from the tradition has given rise to the public forefront where a socially distant meeting isnt so distant any-longer.

Nonetheless, beauty is a gesture, a symbol of self-assurance that transcends to self-care while remaining true to creating something more modern. The silver lining to 2020, is that given the endless hours spent at home, many Americans came across a new found peace and serenity. In turn, a straight path forward to curate and maintain a healthy lifestyle.

To mark the most memorable moments, home workouts did not go unnoticed. In addition, binge buying had its place to fill a chapter of satisfaction. But what about beauty regimes?Well, that continued to hold its own during this era of self-isolation and wellness. After all, strong willed optimism to return to the once dreaded daily-grind will bestow itself upon us in the near future.

Over the years, innovative treatments in skincare brought forth a fresh new set of revolutionary products and devices that have been entering the market segmentation. For example, Dr. Dennis Gross has pioneered an LED (light emitting diode) device that not only succeeds in its wrinkle reducing and acne fighting purpose, but rather transports you to a world of futuristic rejuvenation as you place this sci-fi mask on your face.

As businesses across the country begin to open their doors again, Dr. Barbara Sturm is providing extensive knowledge and intricate detail into the scientific formulation of serums such as her Anti-Pollution Drops that replenishes skin from HEV blue light, ejected from digital devices; something mankind cannot escape in modern times.

In fact, celebrity makeup artist Marie-Jose Leduc attests that using pure natural oils is the best path forward. Ms Leduc recently launched Odile, a skincare line where the products are a cocktail of active botanicals and devotedly organic. Let go of the harsh chemicals Leduc tells us. Scale it back a little and go gentle. More to the point, Gen Z advocates sustainability, a key factor to the largely lucrative industry.There is a small group of us who look at the big picture. I cant make money knowing that I am harming the environment, Leduc preaches with strength to pave an organic pathway for those that follow.

Now that the world is getting closer and closer, the next chapter is confidence and hope. Americans are rediscovering comfort and security found in beauty and wellness. As tough as 2020 has been, people are feeling refreshed and replenished to take on the next chapter. To help you begin your fresh skincare and wellness regiment, I have reviewed a handful of the best products and services developed to stand the test of time.

Armani Beauty:

Armani beauty Crema Nera Supreme Reviving Cream ($400)

Armani Beauty- Crema Nera Supreme Reviving CreamThe Supreme Revivng Cream is part of a complete Crema Nera skincare ritual that awakens the skin with luxurious, hydrating formulations. The ranges powerful fusion of nature and revolutionary technology imparts both instant results and lasting benefits to the skin. The powerful, exclusive Reviscentalis ingredient defines the Crema Nera collection, and is infused throughout the full range. Prized for its healing and medicinal powers, an extract from the Reviscentalis plant is able to uncover radiant skin and a more youthful appearance. $400

ARTIS:

Perfect for applying foundation, skincare, bronzer and contour with some glam. Its proprietary ... [+] animal-free CosmeFibre can be used with liquids, creams and powders across makeup and skincare formulas.

Artis has created elegance and glamour this holiday season with their limited- edition Elite Oval 7 brushes, each encrusted with a unique design of Swarovski Crystals!The EmeraldCrystal Elite Mirror Oval 7 Brush is adorned with 70 crystalsrichly pigmented soft-green Swarovski crystals, while theThe translucent Crystal Elite Mirror Oval 7 Brush is decorated with 362 translucent-white Swarovski crystals, and the Red Crystal Elite Mirror Oval 7 Brushis filled with 362 ravishing ruby red crystals, all options bring to life a classic holiday color choice thatshines on any bathroom counter. EmeraldCrystal Elite Mirror Oval 7 Brush-$200,Translucent Crystal Elite Mirror Oval 7 Brush$250 andRed Crystal Elite Mirror Oval 7 Brush$250

BABOR:

Babor

DOCTOR BABOR Power Serum Ampoules: This seven day intensive treatment deeply hydrates the skin with four types ofhyaluronic acids of varying weight to plump the skins surface and improve skin elasticity.The Hyaluronic acid + Booster Tripeptides work together to deliver intense hydration and effectively plump the skin. Helps improve skin elasticity with long lasting effects. $49.95

BIOEFFECT:

tk

To celebrate the 10-year anniversary of BIOEFFECT and the brands award-winning, best-selling EGF Serum, BIOEFFECT launched a 50 mL Limited Edition EGF Serum produced in their new patented black barley. Containing only seven ingredients, this serum is three times the size of the original and features double the concentration of EGF proven to reduce the appearance of wrinkles and fine lines as well as plumps skin to increase density and thickness. The unique bottle is custom-sculpted and designed by renowned Icelandic-born, Brooklyn-based artist, Shoplifter, who designed the bottle to show how the magic of nature and science can merge and influence a work of art. $495 USD

Biophile Skin:

Created by maverick creative scientist and award-winning clean beauty pioneer Alison Cutlan, along ... [+] with seasoned business executive Grace Fooden, the biophile brand synthesizes traditional ecological wisdom with modern science in an alchemical process called biofermentation

Biophile is a new generation of biologically advanced, sustainable skincare that works to balance the microbiome, activate the skins regenerative abilities and strengthen skin barrier function. Biophiles breakthrough trio of productsRoot Bionic Refining Essence, Bio-Shroom Rejuvenating Serum, and Bio Barrier Nourishing Oilfeed the skin with probiotic bacteria and botanicals, fungi and superfoods to boost skin immunity and hydration, increase cellular energy, reduce wrinkles and pigmentation, and increase smoothness. Each biophile product is designed to work synergistically to bring skin to life .First, the Root Bionic Refining Essence resurfaces and regenerates to prepare skin for the award-winning Bio-Shroom Rejuvenating Serum. Next, the Bio-Shroom Serum feeds and supports the skin with three powerful mushrooms and age-defying actives and peptides, supporting the skins barrier and microbiome. Finally, the Bio Barrier Nourishing Oil strengthens and fortifies for a plump-and-seal effect. $125

BeautyBio:

BeautyBio

Professional-grade stainless steel, dual-ended Cryo Roller harnesses the natural power of ice-cold temps to depuff, tighten and detoxify skin for a clearer, sculpted, more radiant appearance.USD: $85.00

Dr. Barbara Strum:

Courtesy of Dr. Barbara Sturm Dr. Barbara Sturm Anti-Pollution Drops ($145) strengthen and calm ... [+] skin while also providing protection from damaging HEV blue light.

Dr. Barbara Sturm HEV is a blue light thats emitted by digital devices, and it penetrates deep into the skin making it potentially more dangerous than UV rays. Over time, it can compromise skin barrier function, triggering an inflammation cascade that causes premature aging, uneven tone, loss of firmness, dryness, impaired skin healing, sensitivity and even breakouts. HEV light exposure is a growing danger for our skin. In fact, during quarantine, US-based Internet service providers reported screen time increases of up to 50% as people turn to their phones to stay connected and informed. Dr. Barbara Sturms Anti-Pollution Drops contain a Skin Protect Complex that strengthens the skins defenses, Cocoa Seed Extract that forms a shield to protect against UV rays, and the brands signature ingredient, Purslane, to help calm irritation. Dr. Barbara Sturms propriety blend of Hyaluronic Acid also provides hydration on both deep and surface levels, which is essential to maintaining healthy barrier function. To protect your skin from blue light, apply Dr. Barbara Sturms Anti-Pollution Drops after cleansing and before applying face cream, and reapply as needed throughout the day. $145 USD

Courtesy of Dr. Barbara Sturm

Dr. Barbara Sturm Anti-Pollution Drops ($145) strengthen and calm skin while also providing protection from damaging HEV blue light.

Dr. Dennis Gross Skincare:

Dr. Dennis Gross LED FaceWare Device

Dr. Dennis Gross skincare- This FDA-cleared SpectraLite FaceWare Pro mask is a LED mask offering professional light therapy at the comfort of your home. A combination of 100 light emitting diodes in red mode + 62 LED lights in blue mode work together to smooth wrinkles, diminish discoloration, and clear acne for a beautiful, youthful complexion. Red light emitting diode penetrate deep within skins dermis to boost collagen production. Blue light emitting diode destroy P. acnes bacteria to reduce redness, inflammation, and prevent future breakouts. Within days, see a reduction of acne. In 2 weeks, experience a clearing of mild to moderate acne and fading lines. Optimal skin results occur after a 10 week course of treatment. $435 USD

Dr. Loretta:

Dr. Loretta

This advanced sunscreen protects skin from the four external factors responsible for more than 85% of skin aging pollution, light, climate and irritants. Lipochroman provides antioxidant protection from free radical damage caused by pollution and UV radiation the leading causes of fine lines and age spots. Indian ginseng extract protects skin from HEV light emitted from the sun and electronic devices, while peptides hydrate and firm skin. Zinc oxide protects skin from UVA/UVB and irritants.$50

Franz Skincare USA:

Franz Skincare Premium Microcurrent Facial Dual Mask

The Franz Microcurrent Facial Dual Mask is an award-winning microcurrent facial treatment delivered in a dual-layered mask (set of 2 treatments). The first of its kind, this dual mask system is powered by water energynot batteriesto create tiny waves across skin, letting the masks essences go 6x deeper than the leading face mask* for max results. Price: $50

Garden Apothecary:

Ground facial serum, handmade fresh from our farm

Garden ApothecaryHigher Ground botanical serumis formulated by our in-house botanist, offering the ultimate nourishment with everyday use.With rich phytonutrients, powerful antioxidants, and replenishing peptides, this hydrating serum is dense with healing botanicals, straight from our organic farm. We sustainably grow the saffron that goes into each and every bottle we make here in Half Moon Bay, CA.$108.

GOOPGENES BY GOOP:

GOOPGENES All-In-One Nourishing Face Cream is a luscious treat for the skin and a clinically tested ... [+] supercream that leaves skin looking and feeling soft, smooth, firm, and moisturized for up to 48 hours.

GOOPGENES BY GOOPThis luxuriously rich, all-in-one super-cream melts into skin, leaving it deeply nourished with a unique whipped texture that makes it feel like an invisible second skin. The clinically tested formula is made with seven highly active botanicalsincluding Schisandra fruit, Illipe butter, Caviar lime, and Squalenethat work synergistically to leave skin ultra-moisturized, soft, supple, smooth, firm, and even-toned. A megadose of plant-based ceramides promotes noticeable radiance while smoothing, firming, and hydrating. After just one use, 100% of women experienced significant improvement in hydration. After four weeks of use, 100% showed significant improvement in skin firmness and 94% said their skin appeared brighter. Fragrance-free. $95 USD

iS CLINICAL:

CLINICAL Youth Body Serum

NEW iS CLINICAL Youth Body Serum-This refreshing lightweight serum mist gently absorbs into the skin providing powerful hydration and antioxidant protection against environmental aggressors. The purest form of Hyaluronic Acid, potent extracts of Watermelon, Blue-Micro Algae, Licorice Root and Holy Herb, are combined with essential Vitamin B5, and our proprietary Extremozymes to create a unique and effective formula designed specifically for the body. Much more than a moisturizer, this nourishing treatment leaves skin feeling fresh, soft, and more hydrated. USD$120

KLUR:

Organic hempseed, avocado, and grapeseed oils deliver reparative nutrients to parched areas, while ... [+] providing replenishment and protection against daily moisture loss featuring a comforting aromatic bouquet scent of Neroli Orange Blossom, Bulgarian Rose, and French Lavender.

Klur This uniquely fragrant multi-purpose botanical body oil is formulated to nourish, firm and replenish skin.A comforting aromatic bouquet of Neroli Orange Blossom, Bulgarian Rose, and French Lavender impart a delicate floral yet earthy, gender-fluid aroma. Organic hempseed, avocado, and grapeseed oils deliver reparative nutrients to parched areas, while providing replenishment and protection against daily moisture loss. Thus, transforming skin to its most radiant state. $70 USD

Lancer Skincare:

Lancer Legacy Youth Treatment revitalizes the very look of skin, engineered to promote a ... [+] healthy-looking complexion in five essential functions: supporting rejuvenation, recapturing skin vitality, and providing a moisture barrier, water saturation and antioxidant defense.

Lancer Legacy Youth TreatmentThis luxurious skin rejuvenation treatment saturates the epidermis with moisture and in combination with advanced factors, elicits a fresh, rejuvenated and healthy-looking complexion. A compound of precious saffron and sake help to promote a brighter, more even-looking skin tone. Next generation amino and hyaluronic acids enhance natural moisture retention for supremely supple and renewed skin.Lines appear softer and smoother, skin looks firmer, and the complexion glows with innate vitality. After polishing and cleansing, apply a generous amount to clean, dry skin using upward strokes sweeping onto the entire face, neck and dcollet and pat gently into the skin for one minute. Over 30 ingredients, sourced from around the world, engineered into 5 revolutionary complexes: Youth GF Complex, Firming Mesh Complex, MitoSmooth Compound, Aquadermal Complex, and SativusBright Compound. Price: $1,000

LightStim:

LightStim for Wrinkles is available at major prestige retailers including Sephora, Nordstrom, Neiman ... [+] Marcus, Revolve and more, as well as LightStim.com.

LightStim-The restorative benefits of sunlight have been known for thousands of years, but in more recent history we have become aware of the damage that can be caused by excessive exposure to UV. Often called red light therapy and generally referred to as low-level light therapy or photobiomodulation among researchers and clinicians, this treatment contains no UV and utilizes only clinically proven beneficial wavelengths (or colors) of light to treat the skin. Studies performed over many decades, including those conducted by NASA, have shown that the human body has the ability to absorb light through the skin and other body tissues and convert it into energy. This is important, because as we age our skin loses the energy needed to maintain its plump, youthful appearance. As a result, fine lines and wrinkles form, and skin appears slack. The key to LightStim for Wrinkles' effectiveness is its patented MultiWave technology which allows for a more thorough and comprehensive treatment. The device simultaneously emits 4 different wavelengths of UV-free therapeutic light energy. Amber, deep red, light red and infrared wavelengths nourish the skin from within, filling in fine lines and wrinkles, and over time reducing and even eliminating them all in an easy-to-use, portable hand-held device. $249

Luzern:

Nuit Cleaning Emulsion: Hydrates as it cleans, leaving skin glowing and revitalized

Luzern- Nuit Cleansing EmulsionNuit Cleansing Emulsion. The ultimate pampering and rejuvenating entre' into your evening regimen. Nutrient-rich Alpine extracts are suspended in this ultra-rich cleansing balm.Blended with 6 nourishing oils to help decongest skin without disrupting its delicate protective barrier. Melts on contact with the skin's warmth to dissolve away impurities, makeup, and pollution to prepare it for nighttime renewal. Nuit Cleansing Emulsion: MSRP $135.00

MARA:

MARA's limited edition Sea the Glow Radiance Duo featuring a full-size luxury Universal Face Oil ... [+] and a travel size luxury Algae Retinol Face Oil developed to work in tandem to soften signs of aging, texture and dark spots while delivering fatty acids and phytonutrients for the ultimate hydration and glow.

MaraOur two best selling luxury face oils to hydrate and treat your way to a gorgeous glow this holiday season! This limited edition Sea the Glow Radiance Duo has a full size Universal Face Oil and a travel size Algae Retinol Face Oil so you can treat yourself or someone you love to the gift of good skin this holiday. These two products were developed to work in tandem. Travel size Algae Retinol Face Oil is a nighttime treatment that softens signs of aging, texture and dark spots; Universal Face Oil is filled with fatty acids and phytonutrients for insane hydration and glow. $105 USD

NELI Naturals:

NELI Naturals Skincare Collection

NELI, meaning the truth will be revealed, is an effective, clean skincare line with an attainable price point. Created alongside dermatologists, the cruelty-free (Leaping Bunny Certified), vegan, paraben-free, all-natural ingredient product line consists of a Gentle Facial Cleanser, AHA/BHA Superfruit Hydrating Scrub, Collagen Peptide SPF Daily Moisturizer, 4.25% Retinoid Collagen Night Moisturizer and an Apple Stem Cell Hydrating Eye Cream. The glow boosting, anti-aging collection is enriched with essential ingredients such as collagen, hyaluronic acid and berry antioxidant extracts to improve your skin barrier while maintaining a healthy and hydrated complexion.$102 USD

NON GENDER SPECIFIC:

A luxurious moisturizing face cream with 23 powerful botanicals

Non Gender Specific Everything Cream is a luxurious moisturizing face cream that works to deliver phytonutrients and hydration deep into the skin, thanks to 23 powerful botanicals. This formula works to nourish the skin with natural oils that absorb quickly and are never greasy, leaving skin feeling soft withthe appearance of brighter skin, refined pores andreduced redness.USD$58

PMD Beauty:

The new Personal Microderm Elite Pro is a cordless option for effortless, on-the-go beauty featuring ... [+] an extended range of discs for all your exfoliation needs.

PMD BeuatyThe newly launched Personal Microderm Elite is the brands first microderm device that is wireless and rechargeable. Get rid of dull skin with the revolutionary microdermabrasion tool - on the go. The Elite offers a customizable treatment for your unique skin type. After just one treatment it will reveal smoother, softer skin. Now you can reduce fine lines and wrinkles, increase hydration and even out skin texture at a fraction of an in-spa treatment cost. $299

Phyto-C:

evens-out the appearance of uneven skin tone

PHYTO-CThe new HYPER-C now includes AHAs (Glycolic and Lactic Acid) for even brighter, smoother skin! Formulated with HA technology plus peptides and pure Vitamin C, Hyper-C works to rejuvenate the appearance of dull looking skin by using the highest concentration of Vitamin C (20%) clinically tested to provide the maximum amount of antioxidant benefits to the skin. The unique HA technology, which stands for HYPER absorbing hyaluronic acid delivers essential ingredients where you need them most at the perfect absorption rate. $70

SAINT JANE:

Clean botanicals are paired with rich concentrations of full-spectrum hemp to enhance its benefits, ... [+] making this powerhouse duo the ultimate skin-transforming routine for calm, nourished, and glowing skin

Saint Jane THE IDEAL DUO Layerthese two award-winning skincare powerhousesfor your bestskin days.Start with The C-Drops for 20% active Vitamin C plus soothing hemp extract to resurface and brighten. Follow with Luxury Beauty Serum on top for deepnutrients and intense moisture.They work together to deliver exactly what your skin needs for complete nutrition throughout your day. $200.00

Sunday Riley:

Pink Drink Firming Resurfacing Essence

Sunday Riley A power drink for your skin, this peptide-infused essence resurfaces, balances, and firms the look of your skin (while drenching it in advanced green tea, antioxidant support). Peptides help firm the skin, while fermented honey and botanical extracts balance the skins natural microbiome and resurface the skin. $48.00

Tata Harper:

This limited edition duo is a natural face lift in a bottle, engineered with the most lifting and ... [+] firming technology. Includes the Boosted Contouring Serum and Boosted Contouring Eye Balm.

Tata HarperBoosted Contouring SetThis hyper-potent duo including the Boosted Contouring Serum and Boosted Contouring Eye Balm transforms thelook of mature, sagging skin to restore a youthfully firm, lifted look on both the face, dcollet, and under eye area. Best used for loss of firmness/ elasticity, fine lines & wrinkles, and dryness.$270.00

3LAB:

3LAB Super Cream

Super Cream is a super-powered skin booster with the most advanced technology, targeted delivery system unique to 3LAB.This luxurious, ingredient-rich cream delivers elastin producing peptides and targeted repair in a matter of days. X50 and Intelligent Targeting Device (ITD) deliver antioxidants and peptides directly to the source of the problem, combating fine lines, wrinkles and skin imperfections with quick, dramatic results. Always on the cutting edge of skin care technology, 3LAB prides itself on offering serious skin care solutions that are efficacious and made with the highest quality ingredients.With Super Cream, 3LAB is one of the first to introduce smart technology to skin care.Think of it like a GPS system programmed into your skin cream. Combined with 3LABs signature Bio-Engineered Renewal Complex and Apple Stem Cell Technology, the key ingredients are encapsulated within the cream and when applied, it targets tired, stressed-out, and aged cellsonly targeting the cells that need repair. The concept was adapted from the pharmaceutical industry where smart delivery technology enables medications to target diseased cells.$900 USD

U Beauty:

"U Beauty and Artis Holiday Duo Limited Edition Set

U Beauty and Artis Holiday Duo Limited Edition Set U Beauty, the luxury, clean, science-backed skincare line dedicated to simplifying your skincare routine, and Artis, the beauty brand best known for their innovative makeup and skincare brushes, will launch a limited-edition set for the holiday 2020 season. For Holiday 2020, U Beauty is pleased to present an exclusive, limited-edition gift set in collaboration with Artis. The brands joint offering will pair U Beautys recently launched 50ml The SUPER Smart Hydrator with Artis Palm Brush Mini.Price: $168

Valmont:

A rich replenishing balm created to provide intense nourishment for even the driest skin.

Valmont - PRIMARY POMADEThis ointment immediately and intensely nourishes the skin. Thanks to the latest technology, its incredibly fine texture penetrates the skin at a rapid speed, visibly healing dry or irritated areas. It replenishes lipids, restores the skins protective barrier function, and softens dry skin. The skin is smoother, more supple and comfortable. Retail price: $275

VENeffect:

Veneffect harnesses the power of phytoestrogens to offset the signs of hormonal aging

MoisturizerVeneffect Intensive Moisturizer ($185USD) is a potent blend of plant based phytoestrogens, emollients and peptides to address the effects of hormonal aging on skin.Created by sister duo, Cecil Booth, a beauty industry veteran,and Rebecca Booth, M.D., an OB/GYN specializing in hormonal wellness,their line harnesses their experiences professionally and as women to optimize hormonal vitality throughout the month and as women uniquely age.They call this phenomenon the Venus Effect, thus their brand, Veneffect.$185 USD

VENN Skincare:

ADVANCED MULTI-PERFECTING RED OIL SERUM

VENN Skincare- A multi-correctional face oil serum, strategically formulated using 34 root extracts, botanicals, and essential oils to deliver a category-defining, comprehensive skin benefits. 100% of the formula are efficacy-driven bioactives. Inspired by Korea's traditional herbal first aid ointment, the key ingredients include Lithospermum Erythrorhizon (Gromwell) Root Extract and Angelica Gigas (Korean Angelica) Root Extract that are fermented for 150 hours at low temperature for amplified delivery and performance on the skin. Clinically tested to hydrate skin for up to 24 hours, improve skins elasticity and firmness, and instantly increase skins radiance. $115 USD

Read more here:
The New Generation Of Beauty - Forbes

Skin Stem Cells Comments Off on The New Generation Of Beauty – Forbes | November 18th, 2020

Market Report Summary

For Full Information -> Click Here

Read Full Press Release Below

Spinal Cord Trauma Treatment Market: Global Industry Analysis 2012 2016 and Forecast 2017 2025is the recent report of Persistence Market Research that throws light on the overall market scenario during the period of eight years, i.e. 2017-2025. According to this report, Globalspinal cord trauma treatment marketis expected to witness significant growth during the forecast period.

This growth is expected to be primarily driven by increasing incidence of spinal cord trauma, and increasing government support to reduce the burden of spinal cord injuries. Additionally, development of nerve cells growth therapy is expected to boost the market in near future.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/17353

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/17353

The global market for spinal cord trauma treatment is is estimated to be valued at US$ 2,276.3 Mn in terms of value by the end of 2017. The global spinal cord trauma treatment market is expected to expand at a CAGR of 3.7% over the forecast period to reach a value of US$ 3,036.2 Mn by 2025end.

Global Spinal Cord Trauma Treatment Market: Trends

Global Spinal Cord Trauma Treatment Market: Forecast by End User

On the basis of end user, the global spinal cord trauma treatment market is segmented into hospitals and trauma centers. Hospitals segment dominated the global spinal cord trauma treatment market in revenue terms in 2016 and is projected to continue to do so throughout the forecast period.

Hospitals and trauma centers segments are expected to approximately similar attractive index. Hospitals segment accounted for 53.2% value share in 2017 and is projected to account for 52.5% share by 2025 end.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/17353

Global Spinal Cord Trauma Treatment Market: Forecast by Injury Type

On the basis of injury type, the global spinal cord trauma treatment market is segmented into complete spinal cord injuries and partial spinal cord injuries.

Partial spinal cord trauma treatment segment is expected to show better growth than the completed spinal cord treatment segment due to higher growth in the incidence rate of partial spinal cord trauma than the complete spinal cord trauma. With US$ 1,870.3 Mn market value in 2025, this segment is likely to expand at CAGR 3.8% throughout the projected period.

Global Spinal Cord Trauma Treatment Market: Forecast by Treatment Type

On the basis of treatment type, the global spinal cord trauma treatment market is segmented into corticosteroid, surgery, and spinal traction segments.

Surgery segment dominated the global spinal cord trauma treatment market in revenue terms in 2016 and is projected to continue to do so throughout the forecast period. Surgery segment is the most attractive segment, with attractiveness index of 2.6 over the forecast period.

Global Spinal Cord Trauma Treatment Market: Forecast by Region

This market is segmented into five regions such as North America, Latin America, Europe, APAC and MEA. Asia-Pacific account for the largest market share in the global spinal cord trauma treatment market.

Large patient population due to the high rate of road accidents and crime is making the Asia Pacific region most attractive market for spinal cord trauma treatment. On the other hand, MEA and Latin America is expected to be the least attractive market for spinal cord trauma treatment, with attractiveness index of 0.3 and 0.5 respectively over the forecast period.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Website https://www.persistencemarketresearch.com

More here:
The Spinal Cord Trauma Treatment Market To Walk The Path Of Double Digit CAGR Of 3.7% - KYT24

Spinal Cord Stem Cells Comments Off on The Spinal Cord Trauma Treatment Market To Walk The Path Of Double Digit CAGR Of 3.7% – KYT24 | November 18th, 2020

For the first time, researchers at the Center for Cell-Based Therapy (CTC) in Ribeiro Preto, Brazil, have identified a non-hereditary mutation in blood cells from a patient with GATA2 deficiency.

GATA2 deficiency is a rare autosomal disease caused by inherited mutations in the gene that encodes GATA-binding protein 2 (GATA2), which regulates the expression of genes that play a role in developmental processes and cell renewal.

An article on the study is publishedin the journalBlood.

The non-hereditary mutation may have acted as a natural gene therapy which prevented the disease from damaging the process of blood cell renewal. This meant that the patient did not develop such typical clinical manifestations as bone marrow failure, hearing loss, and lymphedema.

The researchers say that the findings pave the way for the use of gene therapy and changes to the process of checking family medical history and medical records for families with the hereditary disorder.

Luiz Fernando Bazzo Catto, first author of the article, said: When a germline [inherited] mutation in GATA2 is detected, the patients family has to be investigated because there may be silent cases.

The discovery was made when two sons were receiving medical treatment at the blood centre of the hospital run by FMRP-USP, both of which, in post-mortem DNA sequencing, showed germline mutations and GATA2 deficiency diagnosis. The researchers used next generation sequencing to estimate the proportion of normal blood cells in the fathers bone marrow, preventing clinical manifestations of GATA2 deficiency, and of cells similar to his childrens showing that 93% of his leukocytes had the mutation that protects from the clinical manifestations of GATA2 deficiency.

Following the sequencing of the fathers T-lymphocytes, the researchers found that the mutation occurred early in their lives and in the development of hematopoietic stem cells, which have the potential to form blood.

They also measured the activity of the blood cells, to see if they could maintain the activity of inducing normal cell production for a long time, by measuring the telomeres of his peripheral blood leukocytes. Telomeres are repetitive sequences of non-coding DNA at the tip of chromosomes that protect them from damage. Each time cells divide, their telomeres become shorter. They eventually become so short that division is no longer possible, and the cells die or become senescent.

The telomeres analysed by the researchers were long, indicating that the cells can remain active for a long time.

The researchers hypothesised that the existence of the somatic mutation in the fathers blood cells, and its restoration of the blood cell renewal process, may have contributed to the non-manifestation of extra-haematological symptoms of GATA2 deficiency such as deafness, lymphedema, and thrombosis.

Professor Rodrigo Calado, a corresponding author of the article, said: A sort of natural gene therapy occurred in this patient. Its as if he embodied an experiment and a medium-term prospect of analogous gene therapy treatment in patients with GATA2 deficiency.

The findings help us understand better how stem cells can recover by repairing an initial genetic defect.

Recommended Related Articles

Here is the original post:
Non-hereditary mutation acts as natural gene therapy for GATA2 deficiency - Health Europa

Bone Marrow Stem Cells Comments Off on Non-hereditary mutation acts as natural gene therapy for GATA2 deficiency – Health Europa | November 18th, 2020

Chamber Member Update

Boca Raton, FL, November 17 Every three minutes a person in the United States is diagnosed with a blood disease such as leukemia, immunodeficiencies and sickle cell. To deliver cutting-edge, lifesaving therapy services for stem cell transplantations and improve patient outcomes, the Gift of Life Marrow Registry has announced the newly opened the Gift of Life Center for Cell and Gene Therapy.

Located at Gift of Lifesheadquarters in Boca Raton, Fla., theCenter will provide transplant physicians, researchers, and cell and gene therapy developers with the donor cell products they need to help more patients than ever before. One of the Centers signature services will be a biobank of off-the-shelf, on-demand cell therapy products available for transplantation, as well as those for engineering and ethical research. The inventory will be comprised of products collected from super donors with high frequency genetic characteristics sourced from the Gift of Life Marrow Registry. These cells will be tested, processed and cryopreserved by the Centers cellular therapy laboratory.

Another specialty service is the Centers innovation program, which will collaborate with world-renowned South Florida research institutions to improve transplant outcomes, develop processes for cell expansion and much more.

While many advancements have been made in stem cell treatments for those with blood diseases, there are still critical barriers that can impeded success, said Gift of Life CEO and Founder Jay Feinberg.

The only registry in the world started and run by a transplant survivor, Gift of Life has pioneered key innovations in the stem cell transplantation and donation process. Last April, the organization become the first registry to operate an in-house stem cell collection center that has not only helped to bring stem cell donors to collection faster, but also greatly improves the experience for donors. Gift of life is also the first registry to use buccal cheek swabs at recruitment drives instead of blood draws and the first to do mobile registration, including the creation of a smart phone app to register individuals quickly and effectively.

Gift of Lifes overarching mission isto democratize celltherapy and ensure that every patient has an equal opportunity to receive the treatment that can save their lives, said Feinberg. Doing so requires innovation, passion and an entrepreneurial approach to the challenges at hand and we are excited to draw upon our 30 years of expertise as we embark on this next phase of our work.

About Gift of Life Marrow RegistryGift of Life Marrow Registry is a 501(c)(3) nonprofit organization headquartered in Boca Raton, Fla. The organization, established in 1991, is dedicated to saving lives by facilitating bone marrow and blood stem cell transplants for patients with leukemia, lymphoma, and other blood-related diseases. To learn more about Gift of Life Marrow Registry, visitwww.giftoflife.org.

Excerpt from:
gift of life marrow registry announces new center for cell and gene therapy - The Boca Raton Tribune

Bone Marrow Stem Cells Comments Off on gift of life marrow registry announces new center for cell and gene therapy – The Boca Raton Tribune | November 18th, 2020

A succinct analysis of market size, regional growth and revenue projections for the coming years is presented in GlobalStem Cells Marketreport. The study further sheds light on major issues and the new growth strategies implemented by manufacturers that are part ofcompetitive landscape of the studied market.Thereport offers key trends, investment opportunities and drivers in Global Stem Cells Marketwith the latest market intelligence by adopting primary and secondary research methods. It also includes strategies adopted in the context of acquisitions and mergers, and business footprint extensions.

In order to provide more exactmarket forecast, the report comprises a complete research study and analysis ofCOVID-19 impact on the Global Stem Cells market. It also considers the strategies that can be adopted to deal with the situation.

Get sample [emailprotected] https://www.kdmarketinsights.com/sample/3333

Competitive Landscape and Stem Cells Market Share Analysis:

The competitive landscape of the Stem Cells market provides data about the players operating in the studied market. The report includes a detailed analysis and statistics onprice, revenue and market share of the playersfor the period 2020-2025. The major players covered are as follows:

Thermo Fisher Scientific Inc.

Cellular Engineering Technologies Inc

Qiagen N.V

Sigma Aldrich Corporation

Becton, Dickinson and Company

Miltenyi Biotec

International Stem Cell Corporation

Stem Cell Technologies Inc.

Pluristem Therapeutics Inc

Medtronic, Inc

Zimmer Holdings, Inc.

Bio Time Inc

Zimmer Holdings, Inc

Orthofix, Inc.

Osiris Therapeutics Inc

Others Prominent Players

Key segments covered:

By Product

Adult Stem Cells

Neural Stem Cells

Hematopoietic Stem Cells

Mesenchymal Stem Cells

Umbilical Cord Stem Cells

Epithelial Stem cells and Skin Stem Cells

Others

Human Embryonic Stem Cells

Induced Pluripotent Stem Cells

Others

By Application

Regenerative Medicine

Neurology Regenerative Medicine

Oncology Regenerative Medicine

Myocardial Infraction Regenerative Medicine

Diabetes Regenerative Medicine

Hematology & Immunology Regenerative Medicine

Orthopedics Regenerative Medicine

Other Regenerative Medicine

Drug Discovery and Development

Other Applications

By Technology

Cell Acquisition

Bone Marrow Harvest

Umbilical Blood Cord

Apheresis

Others

Cell Production

Therapeutic Cloning

In-vitro Fertilization

Cell Culture

Isolation

Cryopreservation

Expansion and Sub-Culture

By End-User

Biopharmaceutical

Biotechnology Industry

Research Institutes

By Treatment Type

Allogeneic Stem Cell Therapy

Auto logic Stem Cell Therapy

Syngeneic Stem Cell Therapy

By Banking Type

Public

Private

By Region:

North America (U.S. & Canada)

Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, Indonesia, Taiwan, Australia, New Zealand, and Rest of Asia Pacific)

Latin America (Brazil, Mexico, and Rest of Latin America)

Middle East & Africa (GCC, North Africa, South Africa, and Rest of Middle East & Africa)

Get Complete Research Report with [emailprotected]https://www.kdmarketinsights.com/product/3333/stem-cells-market

Some Important Highlights from the Report include:

Market CAGR during the 2020-2025 forecast period.

Comprehensive analysis on factors that will speed up the growth of Stem Cells marketover the next five years.

Precise estimates about the market size of global Stem Cells market and itscontribution to the parent market.

Precise forecasts for future developments in the Stem Cells industry and shifts in consumer behavior.

The growth of the Stem Cells Market across the Americas, APAC, Europe and MEA.

A detailed analysis of the industry competition and quantitative data on various vendors.

Comprehensive information on variables that will impede the growth of Stem Cells companies.

The Following are the Key Features of Global Stem Cells Market Report:

Market Overview, Industry Development, Market Maturity, PESTLE Analysis, Value Chain Analysis

Growth Drivers and Barriers, Market Trends & Market Opportunities

Porters Five Forces Analysis & Trade Analysis

Market Forecast Analysis for 2020-2025

Market Segments by Geographies and Countries

Market Segment Trend and Forecast

Market Analysis and Recommendations

Price Analysis

Key Market Driving Factors

Stem Cells Market Company Analysis: Company Market Share & Market Positioning, Company Profiling, Recent Industry Developments etc.

Why Choose KD Market Insights?

Provides accurate data and best-in class solutions to our clients.

Offers optimal market predictions and analysis of the business.

Ensures that clients gain unmatched competitive advantage, builds more competent organizations, and ensures enduring outcomes.

Get Discount [emailprotected]https://www.kdmarketinsights.com/discount/3333

About Us:

See the original post:
Stem Cells Market Detailed Analysis by On-going Trends, Prominent Size, Share, Sales and Forecast to 2025 - PRnews Leader

Bone Marrow Stem Cells Comments Off on Stem Cells Market Detailed Analysis by On-going Trends, Prominent Size, Share, Sales and Forecast to 2025 – PRnews Leader | November 18th, 2020

Experts diagnose someone with a blood cancerapproximately every three minutes in the United States. Every year, new blood cancer reports account for10 percent of new diagnoses of cancer.

There are typically three separate types of blood cancers, according toExpress.co.uk. These include leukemia, lymphoma, and myeloma. Signs and symptoms vary based on the form of blood cancer an individual has.

Major factors in leukemia survival rates include early diagnosis and management. Read on to find out more about some of the signs of early blood cancer that you can never miss.

(Photo : Dan Kitwood/Getty Images/Cancer Research UK)CAMBRIDGE, UNITED KINGDOM - DECEMBER 09: A fridge of chemical solutions which contain nutrients that are needed to 'feed' cells and keep them alive for laboratory experiments, at the Cancer Research UK Cambridge Institute on December 9, 2014 in Cambridge, England. Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research. Its vision is to bring forward the day when all cancers are cured. They have saved millions of lives by discovering new ways to prevent, diagnose and treat cancer, and as such the survival rate in the UK has doubled in the last 40 years. Cancer Research UK funds over 4,000 scientists, doctors and nurses across the UK, more than 33,000 patients who join clinical trials each year and a further 40,000 volunteers that give their time to support the work.

According toHematology.org, most blood cancers begin in the bone marrow - where blood is made. These cancers disrupt the development and work of your blood. The stem cells transform into three types of blood cells-white, red, or platelets in the bone marrow.

When anyone has blood cancer, and irregular blood cell's development influences the regular output of blood cells. These cancer cells inhibit the regular functions of your blood such as preventing excessive bleeding or combating diseases. There are three major types of tumors in the blood: leukemia, lymphoma, and myeloma.

Leukemia is a disease that induces the massive development of irregular white blood cells in your blood marrow. This stops bacteria from being combated by the body. These cells often hinder platelets and red blood cells from being formed by the bone marrow.

Plasma cell cancer is myeloma. The antibodies in your body are produced by these white blood cells to combat and resist illnesses and diseases. This cancer can disrupt the immune system of your body and render you susceptible to infection.

Lymphoma hinders the lymphatic function that generates immune cells and removes the body from surplus fluids. Abnormal lymphocytes, along with other cells, can accumulate and gather in the lymph nodes. The body's immune system is weakened by these cancerous cells.

Blood cancer signs differ, like leukemia. Here are certain signs of blood cancer that you can look out for. Many of these signs may sound like the flu and maybe simple to ignore.

If the body produces leukemia, blood cells are destroyed by the disease, so it is impossible for your body to produce safe blood cells. You can experience anemia, and light skin is one of the major signs of anemia. Also, your hands can feel cold to the touch.

A typical symptom in certain diseases is exhaustion. You can see the doctor if you feel more worn out than usual and note a drastic difference in your energy.

Your blood cells aid the functioning of the immune system. The body's immune system does not normally work when certain cells are unhealthy, leading you to get sick more frequently. Frequent fevers and pneumonia are some of the most prominent first signs of leukemia.

You can also keep an eye on any shortness of breath if you are feeling energy depleted. You can take care if you feel short of breath any more quickly during physical exercise.

You can bleed more than usual because the body does not produce enough platelets. You might even more often get a bloody nose. Other modifications connected to your blood that you can look out for include:

No one is sure of what induces leukemia or other cancers of the blood, and there is no means of stopping it. Many factors in the environment, including smoking, pollution, and radiation, may lead to this disease's growth. The past of the family may also play a part in your chance of leukemia.

ALSO READ: Coronavirus Survivors Twice as Likely to Develop Mental Disorders - Study

Check out more news and information on Medicine and Healthon Science Times.

Read more here:
Blood Cancer: Science Reveal Five Easily Missed Signs of Leukemia - Science Times

Bone Marrow Stem Cells Comments Off on Blood Cancer: Science Reveal Five Easily Missed Signs of Leukemia – Science Times | November 18th, 2020

This article was originally published here

Stem Cells Transl Med. 2020 Nov 14. doi: 10.1002/sctm.20-0385. Online ahead of print.

ABSTRACT

Anti-inflammatory and immune-modulatory therapies have been proposed for the treatment of COVID-19 and its most serious complications. Among others, the use of mesenchymal stromal cells (MSCs) is under investigation given their well-documented anti-inflammatory and immunomodulatory properties. However, some critical issues regarding the possibility that MSCs could be infected by the virus have been raised. Angiotensin-converting enzyme 2 (ACE2) and type II transmembrane serine protease (TMPRSS2) are the main host cell factors for the Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) entry but so far it is unclear if human MSCs express or do not these two proteins. To elucidate these important aspects, we evaluated if human MSCs from both fetal and adult tissues constitutively express ACE2 and TMPRSS2 and, most importantly, if they can be infected by SARS-CoV-2. We evaluated human MSCs derived from amnios, cord blood, cord tissue, adipose tissue and bone marrow. ACE2 and TMPRSS2 were expressed by the SARS-CoV-2-permissive human pulmonary Calu-3 cell line but not by all the MSCs tested. MSCs were then exposed to SARS-CoV-2 wild strain without evidence of cytopathic effect. Moreover, we also excluded that the MSCs could be infected without showing lytic effects since their conditioned medium after SARS-CoV-2 exposure did not contain viral particles. Our data, demonstrating that MSCs derived from different human tissues are not permissive to SARS-CoV-2 infection, support the safety of MSCs as potential therapy for COVID-19. AlphaMed Press 2020 SIGNIFICANCE STATEMENT: Human mesenchymal stromal cells (hMSCs) are currently under investigation for the treatment of COVID-19. However, the potential safety profile of hMSCs in this context has never been defined since none has described if they express ACE2 and TMPRSS2, the main host cell factors for SARS-CoV-2 entry, and if they can be infected by SARS-CoV-2. We provide the first evidence that ACE2 and TMPRSS2 are not expressed in hMSCs derived from both adult and fetal human tissues and, most importantly, that hMSCs are not permissive to SARS-CoV-2 infection. These results support the safety of MSCs as potential therapy for COVID-19.

PMID:33188579 | DOI:10.1002/sctm.20-0385

Here is the original post:
Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection - DocWire News

Bone Marrow Stem Cells Comments Off on Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection – DocWire News | November 18th, 2020

16 November 2020

Organoids can be used to study early stages of heart development in mouse embryos, a new study shows.

Researchers from the cole Polytechnique Fdrale de Lausanne, Switzerland, have reported that they were able to produce a mouse heart organoid from embryonic stem cells, which displayed essential features of an early developing heart. They suggested that this reveals a novel application of organoids for studying early embryonic stages of development.

'One of the advantages of embryonic organoids is that, through the co-development of multiple tissues, they preserve crucial interactions that are necessary for embryonic organogenesis,' said Dr Giuliana Rossi, lead author of the study. 'The emerging cardiac cells are thus exposed to a context similar to the one that they encounter in the embryo.'

In their study, published in Cell Stem Cell, the team exposed mouse embryonic stem cells to a mix of three factors involved in promoting heart growth. One week later, the stem cells self-organised into so-called gastruloids:organoids with an embryo-like organisation, which displayed signs of early heart development. The cell aggregatesnot only expressed several genes known to regulate cardiovascular development, but also generated a structure resembling a vascular network. Furthermore, the researchers found an 'anterior cardiac crescent-like domain' in the gastruloids, which even produced a beating heart tissue. Similar to the muscle cells of the embryonic heart, this area was also sensitive to calcium ions.

Organoids have been mostly the focus of research into the generation of adult tissues and organs for pharmaceutical and medical research. In their new publication, Professor Matthias Ltolf and his team suggested that they can also provide a system to study early embryonic stages of the developing heart and other organs, as they preserve important tissue-tissue interactions.

More here:
Organoids mimic the early development of the heart in mouse embryos - BioNews

Cardiac Stem Cells Comments Off on Organoids mimic the early development of the heart in mouse embryos – BioNews | November 18th, 2020

In Exosome Therapeutic Market report, a systematic investment analysis has been performed which forecasts impending opportunities for the market players. The statistical and numerical data that has been included in this market report is represented with the tables, graphs and charts which eases the understanding of facts and figures. A proficient data and excellent forecasting techniques used in this report are synonymous with accurateness and correctness. Exosome Therapeutic Market report is a painstaking analysis of existing scenario of the market which covers several market dynamics. The market study of this global Exosome Therapeutic Market business report takes into consideration market attractiveness analysis where each segment is benchmarked based on its market size, growth rate & general attractiveness.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&rp

Market Analysis and Insights:Global Exosome Therapeutic Market

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

The major players covered in theExosome Therapeutic Marketreport areevox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global.Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Full TOC, Tables and Figures of Market Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&rp

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. Mesenchymal stem cells are dominating in the market because mesenchymal stem cells (MSCs) are self-renewable, multipotent, easily manageable and customarily stretchy in vitro with exceptional genomic stability. Mesenchymal stem cells have a high capacity for genetic manipulation in vitro and also have good potential to produce. It is widely used in treatment of inflammatory and degenerative disease offspring cells encompassing the transgene after transplantation.

Based on therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. Chemotherapy is dominating in the market because chemotherapy is basically used in treatment of cancer which is major public health issues. The multidrug resistance (MDR) proteins and various tumors associated exosomes such as miRNA and IncRNA are include in in chemotherapy associated resistance.

Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules are dominating in the market because bio macromolecules transmit particular biomolecular information and are basically investigated for their delicate properties such as biomarker source and delivery system.

Based on application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. Oncology segment is dominating in the market due to rising incidence of various cancers such as lung cancer, breast cancer, leukemia, skin cancer, lymphoma. As per the National Cancer Institute, in 2018 around 1,735,350 new cases of cancer was diagnosed in the U.S. As per the American Cancer Society Inc in 2019 approximately 268,600 new cases of breast cancer diagnosed in the U.S.

Based on route of administration, the market is segmented into oral and parenteral. Parenteral route is dominating in the market because it provides low drug concentration, free from first fast metabolism, low toxicity as compared to oral route as well as it is suitable in unconscious patients, complicated to swallow drug etc.

The exosome therapeutic market, by end user, is segmented into hospitals, diagnostic centers and research & academic institutes. Hospitals are dominating in the market because hospitals provide better treatment facilities and skilled staff as well as treatment available at affordable cost in government hospitals.

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Customization Available:Global Exosome Therapeutic Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&rp

About Data Bridge Market Research :

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:Corporatesales@databridgemarketresearch.com

Read more:
Exosome Therapeutic Market 2020-2026 Thriving Worldwide || Major Gaints Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron...

Cardiac Stem Cells Comments Off on Exosome Therapeutic Market 2020-2026 Thriving Worldwide || Major Gaints Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron… | November 18th, 2020

Four months after a patient death forced Cellectis to halt one of their off-the-shelf CAR-T trials, the FDA has given them the OK to start dosing patients again.

The Paris-based biotech said they changed the studys protocol to accommodate the agencys concerns, although they will still have to work with investigators to obtain local approval to restart the trial and start recruiting patients again. Prior its halt, the Phase I had sites in New York, New Jersey and Texas.

Cellectis did not disclose what the changes were, but after the initial hold, analysts suggested the company might monitor patient cytokine levels more closely, swap out of one of the chemotherapy drugs used or prevent patients who have previously received an experimental multiple myeloma CAR-T from enrolling.

The companys stock {CLLS} rose 5.6% on the news, from $19.70 to $20.80.

Though partnered with the new upstarts such as Arie Belldegruns Allogene, Cellectis, a 21-year-old company, has been working on off-the-shelf versions to the first CAR-Ts since before those CAR-Ts were approved.

One of three different solo projects now in the clinic, the halted study, MELANI-01, is testing a cell therapy for multiple myeloma. If effective, it could serve as a potentially easier way to manufacture and administer an alternative to the multiple myeloma CAR-Ts now nearing approval from J&J and Legend Biotech and from bluebird bio and Bristol Myers Squibb.

When they announced the hold, Cellectis CMO Carrie Brownstein said that the company had already independently decided to move forward with dose level 1 in the study. The patient who died had been the first to receive dose level 2, an infusion of 3 million cells per kilogram. They developed cytokine release syndrome, the hallmark side effect of CAR-T therapy, and died of cardiac arrest 25 days later.

The dose 1 level involves 1 million cells per kilogram.

The FDA has been on high alert for safety issues in cell therapy trials, and this wasnt the first time theyve paused a Cellectis study. Back in 2017, another patient death paused development of UCART123.

After some protocol adjustments, the therapy was allowed to go back into patients. It is now in a Phase I for blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive blood cancer.

Go here to read the rest:
FDA gives Cellectis all clear after patient death halted off-the-shelf CAR-T trial - Endpoints News

Cardiac Stem Cells Comments Off on FDA gives Cellectis all clear after patient death halted off-the-shelf CAR-T trial – Endpoints News | November 18th, 2020

Another day, another win for Mercks blockbuster Keytruda.

The FDA has granted accelerated approval for the cash cow combined with chemotherapy in triple negative breast cancer, giving the drug the green light in its 18th different cancer. Mondays new indication comes for patients with PD-L1-expressing tumors with a Combined Positive Score of at least 10.

Merck noted that due to the nature of the accelerated approval, the thumbs up is contingent upon confirmatory trials.

Data for the approval first came back in February, when the Keynote-355 trial demonstrated Keytruda plus chemo significantly improved progression-free survival compared to chemo by itself. The study showed that, in the target population with a CPS of at least 10, the combination reduced the risk of disease progression or death by 35% with a median PFS of 9.7 months, against 5.6 months in the placebo arm.

On safety, the February data showed 2.5% of all patients in the drug arm saw fatal adverse events, including cardiac arrest and septic shock, with serious side effects appearing in 30% of patients. Keytruda was discontinued due to adverse events in 11% of patients.

Frontline triple negative breast cancer is a particularly difficult indication to treat, as the growth of the cancer is not fueled by the hormones estrogen and progesterone, or by the HER2 protein. Its one of the rare fields in which Roches PD-L1 Tecentriq has enjoyed a head start over Keytruda and Opdivo, the leaders in the checkpoint race, as Tecentriq is approved in combination with Abraxane for this indication.

Back in May 2019, Merck conceded a failure in the arena after a Phase III study flopped on overall survival. But a few months later, the pharma turned things around after discovering a neoadjuvant regimen of Keytruda and chemo followed by Keytruda monotherapy after surgery induced a higher pathological complete response rate.

Though execs presented that as a positive, some analysts didnt paint as sunny a picture. This past February, when the Keynote-355 topline data was first published, SVB Leerinks Daina Graybosch pointed out that because only patients with a CPS of at least 10 appeared to benefit, instead of a score of at least 1, it wont be able to treat as broad a population as Tecentriq. Roche, she noted, also has about a two-year head start.

A Merck spokesperson also had this to say about the CPS and IC percentages:

In TNBC, we measure PD-L1 with a combined positive score (CPS). The CPS includes staining for tumor cells, as well as tumor-infiltrating immune cells and it is not a percentage. We believe CPS 10 is roughly equivalent to how Roche scores PD-L1+ patients (IC>=1% based on the SP142 assay) on tumor-infiltrating immune cells (IC). The prevalence of the PD-L1 positive population in TNBC whether by CPS of greater than or equal to 10 or IC of 1% is both about 40%.

Keytruda is already one of the best-selling drugs in the world, having notched roughly $3.9 billion in the first half of 2020 alone. Some have predicted the drug may overtake AbbVies Humira as the top seller within the next few years, with the most optimistic estimate pegged for $22.2 billion in sales by 2025.

The rest is here:
UPDATED: Merck's Keytruda nets another approval, this time in triple negative breast cancer. Can it catch up to Tecentriq? - Endpoints News

Cardiac Stem Cells Comments Off on UPDATED: Merck’s Keytruda nets another approval, this time in triple negative breast cancer. Can it catch up to Tecentriq? – Endpoints News | November 18th, 2020

During a 2018 home game against Washington State University, David Shaw, Stanford's football coach, ambled slowly along the sideline, his joints aching.

Wanting to focus on the players and the game, he kept the reason for his lethargy to himself. But two years later, this past Saturday, the sports world learned the full story.

A College GameDay feature on ESPN revealed that the morning before the game, Shaw had been given stem-cell-inducing medication at Stanford Hospital. It was a first step in donating the cells to his brother, Eric Shaw, who was fighting a rare form of lymphoma.

In the opening of the six-minute video, Shaw says he thought, "'God, I hope this works, 'cause if it doesn't, I'm going to lose my brother.'"

Eric Shaw began noticing strange dark patches on his skin in 2011, the year his older brother became Stanford's head football coach. They were everywhere, from head to foot. Later, small tumors popped up all over his body.

"I would have itching attacks where I would end up actually tearing my skin," he says in the video. "I would still scratch at night and end up with bloody arms and legs."

Eric Shaw transferred his medical care to the Stanford Cancer Center in 2013. There, physicians told the financial services marketing professional that he needed to start radiation treatment immediately. It worked, but only briefly: Six months later, the cancer returned.

He was diagnosed with mycosis fungoides, a T cell lymphoma that affects fewer than four in a million people in the United States.

Shaw's physicians began discussing bone marrow transplant. David Shaw was tested as a donor, but he scored only 5 on a 10-point match scale. A worldwide search found closer matches, and Eric Shaw underwent radiation and chemotherapy to prepare for the transplant.

One attempt failed, then another.

"You think you've kind of pulled at the last thread, and there are no more threads, and all I could tell him was that I loved him and that I was there for him," David Shaw says in the video.

But the Stanford physicians had one last weapon: a haploidentical transplant. The recently developed technique uses stem cells, typically from a family member, that are less than a perfect match.

David Shaw underwent a five-day-long process at Stanford Hospital to donate the cells. He received medication that caused him to produce an abundance of stem cells, then gave blood from which the cells were extracted. Those cells were then transplanted into his brother.

This time, it worked.

After 52 days at Stanford Hospital, Eric Shaw finally went home on Nov. 25, 2018. The video shows him being wheeled out as medical staff members cheer him on.

Youn Kim, MD, who treated Eric and heads Stanford's multidisciplinary Cutaneous Lymphoma Clinic/Program, told ESPN: "If he didn't go for this risk, he wouldn't be here...He wouldn't be living."

As the article notes, Stanford physicians Wen-Kai Weng, MD, PhD, and Michael Khodadoust, MD, PhD, also were on the team treating Eric Shaw.

Today, nearly two years later, he remains cancer-free.

"Seven years of battling this disease, and it was over," he says in the video, tears running down his face. "A miracle."

David Shaw shares his brother's joy. As he told ESPN: "Every time I see him, I just smile, you know? Because he gets to be here."

Images of Eric Shaw, left, taken earlier this month, and his brother David Shaw, courtesy of the Shaw family, and Stanford Athletics

See more here:
Stanford coach's quest to save his brother: 'God, I hope this works' - Scope

Bone Marrow Stem Cells Comments Off on Stanford coach’s quest to save his brother: ‘God, I hope this works’ – Scope | November 16th, 2020

MILAN, Italy and NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer (Temferon), presents new preliminaryclinical data from a Phase I/IIa study of Temferon in patients affected by glioblastoma multiforme (GBM) at the 2020 Society for Neuro-Oncology (SNO) Annual Meeting, taking place November 19-22 in Austin, TX.

To date, ten patients were enrolled and eight were treated. Temferon was well tolerated, as suggested by the rapid hematological recovery and engraftment of modified cells observed in all the treated patients. No dose limiting toxicities were identified.

T-cell immunorepertoire changes were observed after treatment with evidence for clonal expansion, including tumor associated clones, suggesting a possible reset of T-cell responses, which are known to play a key role in the tumor-induced tolerance.

Interferon-alpha (IFN-) response was identified across a number of tumor infiltrating myeloid cells while a low concentration of IFN- was detected in the plasma and cerebrospinal fluid (CSF) of patients. This provides evidence that the Temferon built-in control mechanism is working to reduce the risk of IFN- off-target effects preserving the desired in situ biological effects.

Pierluigi Paracchi, Chairman and Chief Executive Officer at Genenta Science, said: These preliminary results are exciting indications of the feasibility, safety and local biological activity of our approach. The data are encouraging and in line with our pre-clinical results, with preliminary evidence of changes in the immune system and that Temferon is well tolerated without systemic toxicities.

Temferon-derived differentiated cells, as determined by vector copy number (VCN) in peripheral blood and bone marrow, were evident within 14 days of treatment and persist in peripheral blood in the long term (up to one year). Preliminary data on tumor specimens at second surgery confirmed the presence of TEMs and suggested that a higher IFN response gene signature may occur after treatment in stable lesions, compared to lesions that progress.

About Genenta Science

Genenta (www.genenta.com) is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for cancer. Temferon is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). TemferonTM, which is under investigation in a Phase I/IIa clinical trial in newly diagnosed Glioblastoma Multiforme patients, is not restricted to pre-selected tumor antigens nor type and may reach solid tumors, one of the main unresolved challenge in immuno-oncology. Based in Milan, Italy, and New York, USA, Genenta has raised more than 33.6 million (~$40 million) in three separate rounds of financing.

The rest is here:
Genenta's Temferon: Evidence of Controlled and Targeted Interferon Expression in Preliminary Phase I/II Clinical Data in Glioblastoma MultiformeData...

Bone Marrow Stem Cells Comments Off on Genenta’s Temferon: Evidence of Controlled and Targeted Interferon Expression in Preliminary Phase I/II Clinical Data in Glioblastoma MultiformeData… | November 16th, 2020